The Tumor Fusion Gene Data Portal (https://www.tumorfusions.org/) [23] was additionally used to assess gene fusion data, revealing comparable frequencies of TMPRSS2-ERG, which is the most frequent form of gene fusion in prostate cancer, in both patient cohorts (Figure 3(d)). This evidence concerns the gene TMPRSS2 and Familial prostate cancer.